Calidi Biotherapeutics Files 8-K for Bylaws and Financials
Ticker: CLDWW · Form: 8-K · Filed: Jul 15, 2024 · CIK: 1855485
| Field | Detail |
|---|---|
| Company | Calidi Biotherapeutics, Inc. (CLDWW) |
| Form Type | 8-K |
| Filed Date | Jul 15, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, financial-reporting, bylaws
Related Tickers: CLDI
TL;DR
Calidi Biotherapeutics filed an 8-K on July 10th for bylaw changes and financials.
AI Summary
Calidi Biotherapeutics, Inc. filed an 8-K on July 15, 2024, reporting events that occurred on July 10, 2024. The filing primarily concerns amendments to its articles of incorporation or bylaws and the submission of financial statements and exhibits. The company, formerly known as First Light Acquisition Group, Inc., is incorporated in Delaware and operates in the biological products sector.
Why It Matters
This 8-K filing indicates updates to Calidi Biotherapeutics' corporate governance and financial reporting, which are crucial for investors to understand the company's operational and legal status.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of corporate actions and financial statements, not indicating any immediate financial distress or significant new risks.
Key Players & Entities
- Calidi Biotherapeutics, Inc. (company) — Registrant
- First Light Acquisition Group, Inc. (company) — Former company name
- July 10, 2024 (date) — Date of earliest event reported
- July 15, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
FAQ
What specific amendments were made to Calidi Biotherapeutics' articles of incorporation or bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the provided text excerpt. The full filing would contain this information.
What financial statements and exhibits are being filed with this 8-K?
The filing states that Financial Statements and Exhibits are being filed, but the specific list or content of these documents is not detailed in the provided excerpt.
When did Calidi Biotherapeutics change its name from First Light Acquisition Group, Inc.?
The company's name change from First Light Acquisition Group, Inc. occurred on April 6, 2021.
What is Calidi Biotherapeutics' Standard Industrial Classification (SIC) code and industry?
Calidi Biotherapeutics' SIC code is 2836, which corresponds to Biological Products (No Diagnostic Substances).
What is the business address of Calidi Biotherapeutics?
The business address is 4475 Executive Drive, Suite 200, San Diego, CA 92121.
Filing Stats: 940 words · 4 min read · ~3 pages · Grade level 12 · Accepted 2024-07-15 16:58:36
Key Financial Figures
- $0.0001 — ch Registered Common stock, par value $0.0001 per share CLDI NYSE American LLC
Filing Documents
- form8-k.htm (8-K) — 45KB
- ex3-1.htm (EX-3.1) — 1KB
- ex3-1_001.jpg (GRAPHIC) — 539KB
- ex3-1_002.jpg (GRAPHIC) — 63KB
- 0001493152-24-027867.txt ( ) — 1095KB
- cldi-20240710_lab.xml (EX-101.LAB) — 36KB
- cldi-20240710_pre.xml (EX-101.PRE) — 25KB
- cldi-20240710.xsd (EX-101.SCH) — 4KB
- cldi-20240710_def.xml (EX-101.DEF) — 26KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CALIDI BIOTHERAPEUTICS, INC. Dated: July 15, 2024 By: /s/ Andrew Jackson Name: Andrew Jackson Title: Chief Financial Officer